Background: Clinical evaluation of the axilla is an area of controversy in current breast
Introduction
Clinical evaluation of the axilla is an area of much debate and interest in current breast cancer research and management. Physical examination of the axilla is notoriously inaccurate; one study demonstrated a 41% error rate overall, with a false-positive rate of 53%. 1, 2 This extremely high error rate supports the practice of tissue diagnosis of axillary metastases prior to proceeding to axillary node dissection. Evidence of axillary metastasis on biopsy affects all modalities of cancer therapeutics and is central to breast cancer staging.
Neoadjuvant chemotherapy is widely accepted as standard therapy for patients with locally advanced breast cancer. The potential surgical and oncologic advantages of systemic therapy prior to defi nitive resection include the conversion of inoperable disease to resectable lesions, potential downsizing of larger tumors and conversion of patients to breastconservation candidates, and in vivo assessment of the response of the tumor to systemic cytotoxic therapy. 3 Until recently, axillary staging for invasive breast cancer was performed by a complete level I and level II lymph node dissection for all patients presenting with a breast cancer diagnosis. However, with the development of lymphatic mapping techniques, sentinel lymph node (SLN) biopsy has become the accepted standard of care for axillary staging of primary earlystage breast cancers. It diminishes the potential morbidity of an axillary dissection, including paresthesias and lymphedema, 4 but with the attendant risks of an operative procedure.
The practice of performing an SLN biopsy prior to neoadjuvant chemotherapy is a focus of debate and is addressed later in this article. Because the presence of axillary disease markedly affects prognosis, recommendations for postmastectomy radiation therapy, and breast reconstruction, [5] [6] [7] assessment of the axilla prior to initiating systemic therapy is preferred, and preoperative axillary staging with ultrasonography and fi ne-needle aspiration (FNA) or core needle biopsy is being widely used (including at our institution).
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Axillary Ultrasonography for Initial Axillary Staging
Compared with sentinel node biopsy or axillary node dissection, axillary ultrasonography with FNA cytology is a far less invasive approach to document nodal involvement, involving a simple nonsurgical examination and minimally invasive biopsy. The technique of axillary ultrasonography for breast cancer evaluation was fi rst described in the European literature about 25 years ago. 18, 19 In conjunction with needle biopsy of abnormal-appearing lymph nodes, FNA has been adopted as a diagnostic modality for detection of axillary metastasis. The specifi city of axillary ultrasonography for metastatic lymph nodes ranges between 70% and 96%, 9, 11, 12, 14, 20 and the sensitivity ranges from 50% to 73%. The specifi city is signifi cantly improved with the addition of needle biopsy of abnormal lymph nodes, up to 100%. 21, 22 Preoperative diagnosis of axillary metastasis is a signifi cant factor in therapeutic decision making, particularly with regard to patient selection for neoadjuvant chemotherapy. Our institutional experience examining the effects of axillary ultrasonography on clinical decision making demonstrates a marked effect in the use of neoadjuvant chemotherapy and multifactorial consequences on the delivery of care for patients in the curative setting. 23 A majority of patients undergoing neoadjuvant chemotherapy undergo defi nitive axillary staging via either axillary ultrasonography with needle biopsy or SLN biopsy prior to initiation of neoadjuvant chemotherapy. The algorithm for preoperative axillary assessment used at Moffi tt Cancer Center is outlined in Fig 1. Axillary ultrasonography and subsequent biopsies are performed by both surgeons and breast-specifi c radiologists at our institution.
Technical Aspects of Axillary Ultrasonography and FNA
Lymph node basins for the breast include the axilla, internal mammary chain, and supraclavicular region. Lymphatic drainage of the breast is primarily into the axillary lymph nodes, which are the most common site of involvement in lymphatic metastasis of breast cancer. Less extensive drainage occurs through the chest wall into the internal mammary nodes, which receive drainage from the medial segments of the breast. Because most of the lymphatic drainage is into the axilla, even medially located breast cancers tend to metastasize to the axilla fi rst. Isolated internal mammary nodal metastasis with complete sparing of the axillary nodes is uncommon. [24] [25] [26] Metastasis to ipsilateral supraclavicular nodes is considered regional metastasis, as lymphatic drainage does not occur directly into the supraclavicular chain. 27 The axillary lymph nodes are divided into three levels using the pectoralis minor as a landmark. Level I, or low axillary nodes, includes nodes located lateral and inferior to the pectoralis minor. Level II, or mid axillary nodes, includes nodes located beneath the pectoralis minor. Level III, or high axillary nodes, includes nodes located medial and superior to the upper medial edge of the pectoralis minor. Level III nodes are also referred to as subclavicular or infraclavicular nodes. The fi rst node to which metastasis occurs is the SLN. The SLN is usually a level I node but may also be an intramammary lymph node or a level II node. Intramammary lymph nodes typically occur in the axillary section of the upper outer quadrant, which is also termed the axillary tail. 27 Staging ultrasonography of the axilla should include careful evaluation of levels I and II as well as the axillary tail of the breast. For examination, the patient is placed supine, with the proximal arm positioned upward adjacent to her head and the distal arm either above her head or on her forehead. Evaluation should be performed with a high frequency linear transducer in the range of 12 MHz to 17 MHz. Rarely, a 9-MHz probe may be necessary for deeper penetration in larger patients. The medial aspect of the axilla extending into the upper outer quadrant, or axillary tail of the breast, should be carefully examined. The pectoralis major and minor are easily visible on ultrasonography (Fig 2) . Level I nodes and intramammary nodes in the axillary tail are easily evaluated. Normal level II nodes, which lie beneath the pectoralis minor, are usually not seen, but abnormally enlarged level II nodes can be readily identifi ed. Our institutional protocol also calls for evaluation of the fi rst and second intercostal spaces, where metastatic internal mammary nodes most commonly occur.
The determination of abnormal lymph nodes is based on several well-established morphologic characteristics rather than the absolute nodal size. Suspicious morphologic characteristics include cortical thickening with concomitant narrowing of the hilum, focal eccentric cortical thickening (bulge in cortical contour), and absence of a central fatty hilum. 28, 29 The nodal contour is also important in differentiating malignant from benign nodes. This distinction is evaluated by determining the ratio of the long-toshort axis. Malignant nodes tend to be more round, possessing a long-to-short axis ratio of less than 2. Nodes with spiculated margins suggest extranodal tumor extension. Nodal color-fl ow Doppler characteristics may also enhance the diagnostic sensitivity of ultrasonography. Furthermore, malignant nodes often lack a hilar blood fl ow pattern. This pattern is characterized by hypervascularity and visualization of multiple feeding vessels for a single lymph node. 30 Lymph nodes with one or more of these characteristics are more likely to be malignant (Fig 3) .
Sonographically abnormal lymph nodes should undergo ultrasound-guided needle biopsy to confi rm the presence of metastasis. At our institution, this process is most often successfully achieved using either 25-gauge 4-cm aspiration needles or 22-gauge 9-cm spinal needles without suction, depending on the depth of the node. Usually, three passes are performed through the most suspicious portion of the cortex. For example, if the lymph node demonstrates focal eccentric cortical thickening, sampling should be from the eccentrically thickened portion (Fig 4) . After it is taken, each sample is handed immediately to a cytotechnologist who then prepares the slides and assesses the adequacy of the samples. Having a cytotechnologist or pathologist present greatly reduces the incidence of insuffi cient sampling; however, this step is not necessary, as the aspirates can be fi xed on slides and sent to pathology for analysis. A negative needle biopsy does not obviate the need for SLN biopsy, as micrometastasis cannot be excluded. Core biopsy is also considered in large nodes, although some consideration is given to the location of the node relative to nearby neurovascular structures. A study by Cho et al 31 marked sonographically abnormal lymph nodes with perioperative wire localization prior to proceeding to SLN biopsy. This prospective study of patients with clinically nodenegative breast cancer suggested that cortical thickness and hilar irregularity were the sonographic features most closely correlated with an abnormal axillary ultrasonography and FNA. In this series of nearly 200 consecutive patients with T1 or T2 lesions, lymph node size was not applied in the detection of nodal metastases.
Predictors of Abnormal Axillary Ultrasonography
The current climate of cost-effi cient health care has prompted clinicians to become cautious of unnecessary studies and procedures. Performing axillary ultrasonography on patients who would more likely have a positive result would increase the study's specifi city as well as limit its overuse. At our institution, data regarding clinical and pathological factors of breast carcinoma that may predict an abnormal axillary ultrasonogram have been studied. 30 In our series, the single most signifi cant factor predictive of an abnormal axillary ultrasonogram was a clinically palpable lymph node. Therefore, although physical examination of the axilla is known to be inaccurate, it is prudent to continue performing clinical assessment and perform axillary ultrasonography for clinically palpable nodes.
Our internal review demonstrated multiple additional factors that are associated with abnormal axillary ultrasonograms. 32 A signifi cant correlation was seen between abnormal axillary ultrasonograms and patients with a larger tumor size. Other studies examining tumor size and its relation to abnormal results have corroborated these fi ndings. 33, 34 One study found that using axillary ultrasonography for T1b or smaller tumors spared SLN biopsy in 6% of patients, whereas patients with T1c tumors were spared biopsy in 17%, ultimately recommending ultrasonography in patients with T1c or greater tumors. 34 Larger tumor size correlated not only with abnormal axillary ultrasonograms but also to positive axillary node needle biopsy. 35 Our institutional data also revealed that patients with higher histologic grade, higher clinical tumor stage, ductal breast histology, and/or infl ammatorytype breast carcinoma were more likely to have an abnormal axillary ultrasonogram. Although lymphovascular space invasion was not associated with abnormal axillary ultrasonograms at our institution, Johnson et al 33 reported it to be associated with a false-negative axillary ultrasonogram. Moreover, these clinicopathological factors remained signifi cant when correlated with a positive axillary node needle biopsy. Although not independently predictive of an abnormal axillary ultrasonogram or positive needle biopsy, these factors may be helpful to the dedicated clinician in selecting appropriate patients to undergo axillary ultrasonographic staging. Our current practice is to perform ipsilateral axillary ultrasonography on patients with an invasive breast cancer diagnosis who have a tumor of 2 cm (T2) or larger on clinical examination.
Clinical Impact of Selective Axillary Ultrasonography
The integration of axillary ultrasonography into a streamlined staging algorithm impacts not only surgical decisions; the results of a positive axillary FNA may be used to select patients for neoadjuvant chemotherapy. Multiple long-term studies have demonstrated the safety and utility of systemic chemotherapy in improving disease-free survival, whether given in the neoadjuvant or adjuvant setting. [36] [37] [38] [39] [40] [41] [42] With this in mind, patients with biopsy-proven disease in the axillary lymph nodes may be considered for neoadjuvant chemotherapy and counseled accordingly, particularly those with borderline resectable disease or those with unifocal disease contemplating breastconserving surgery.
In our single-institution series examining the impact of axillary ultrasonography on clinical practice, axillary ultrasonography was signifi cantly associated with the use of neoadjuvant chemotherapy. 23 Furthermore, the use of selective axillary ultrasonography in routine clinical practice did not increase the time to initiation of defi nitive therapy. 1, 43 In addition, multiple institutions in the United States and Europe have demonstrated a signifi cant cost reduction, 12, 43, 44 despite the addition of ultrasonography and a potential needle biopsy. Theoretically, the integration of axillary ultrasonography into the algorithm decreases the false-negative rate of SLN biopsy; however, this result has not been described in the current literature.
Patients who have an abnormal axillary ultrasonogram and a subsequently positive FNA are con- sidered to be clinically node-positive and are recommended to undergo complete axillary lymph node dissection (ALND) at the time of defi nitive breast surgery. Although there has been much discussion regarding the elimination of ALND, given the recent results of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial, patients with an abnormal axillary ultrasonogram and subsequent positive FNA results cannot be considered node-negative, as in the original study cohort for the Z0011 trial. 45 The recommendation for complete ALND applies to patients undergoing primary surgery or neoadjuvant chemotherapy, including those who have a complete clinical response in the axilla after induction therapy. The elimination of complete ALND as a second operation offsets the cost of a routine negative axillary sonogram.
Advances in SLN Biopsy Technology
The SLN biopsy procedure consists of an intramammary injection of a radiolabeled colloid (Tc-99 sulfur colloid) with or without the addition of a blue dye (lymphazurin or methylene blue) followed by an open surgical biopsy of axillary nodes demonstrating radioactive or blue dye uptake. Ongoing research continues to investigate and refi ne the process of identifying nodes in the axilla, many with the ultimate goals of minimizing the cost and complexity of the nuclear injection or even selecting only the lymph nodes with metastatic disease.
Indocyanine green is currently being explored by several European investigators as an alternative to the blue dye or to both the blue dye and the sulfur colloid, [46] [47] [48] with the possibility of obtaining transcutaneous visualization of the SLN. Another ongoing investigation involves sonographic microbubbles carrying Sudan Black dye for the identifi cation of SLNs via direct visualization or ultrasonographic targeting for percutaneous biopsy. 49 Ongoing research at our institution continues to investigate the possibility of targeted agents for the selective identifi cation of axillary lymph nodes with metastatic disease. 50 These exciting advances in the identifi cation of axillary metastasis have the potential to become new standards in breast cancer surgery, although much of this emerging work is currently limited to animal models or early-phase human trials.
SLN Biopsy in the Setting of Neoadjuvant Chemotherapy
The timing of SLN biopsy in the setting of neoadjuvant chemotherapy is the subject of much debate. Patients with known axillary disease are recommended to have ALND at the time of defi nitive breast surgery. Naturally, the population of patients offered neoadjuvant chemotherapy frequently presents with locally advanced disease, and SLN biopsy is contraindicated in this group. However, as neoadjuvant chemotherapy is increasingly offered in early-stage breast cancer, usually to improve breast-conservation outcomes, clinically node-negative patients are sometimes offered SLN biopsy prior to initiating systemic therapy for staging purposes. 51, 52 SLN biopsy for axillary staging after neoadjuvant chemotherapy has been advocated by some surgical oncology groups as a procedure to be performed at the time of defi nitive breast surgery. 53, 54 However, studies evaluating the use of lymphatic mapping after completion of chemotherapy have reported wide variation in the successful identifi cation of the SLN, ranging from 80% to 99% (Table) . [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] Those in favor of performing SLN biopsy after systemic therapy do so in the hope of sparing patients the morbidity of ALND if they have no residual disease after chemotherapy. In addition, the status of the axilla after chemotherapy has been shown to be of prognostic importance; those patients with axillary clearance after chemotherapy have increased overall and disease-free survival compared with those who have residual axillary disease. 52, 74 However, false-negative rates of SLN biopsy after chemotherapy may be un- (20) acceptably high, ranging from 0% to 22% (Table) . [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] Multiple mechanisms of failure have been suggested, including plugging of breast lymphatics with tumor emboli, architectural distortion of the lymphatics from tumor shrinkage, aberrant drainage patterns to multiple nodal basins, and uneven sterilization of the lymph nodes (where disease in the SLNs is destroyed, leaving residual tumor cells in non-SLNs). 64 Furthermore, there has been persistent concern that the nodal status prior to chemotherapy has independent prognostic value, markedly impacting recommendations for adjuvant radiation therapy. As a result, lymphatic mapping prior to the induction of chemotherapy is frequently utilized to more accurately stage the axilla. An approach of comprehensive and sequential staging of the axilla using a combination of axillary ultrasonography and SLN biopsy in the neoadjuvant population has previously been reported by multiple institutions, both in the United States and abroad.
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Multimodal Approach
Sequential evaluation of the axilla and the use of neoadjuvant chemotherapy are facilitated by a multidisciplinary approach to breast cancer evaluation and treatment. Because axillary staging has a signifi cant impact on treatment decisions for oncologic and reconstructive surgery, chemotherapy, and radiation therapy, early involvement of the entire treatment team is ideal when embarking on a complex course of care.
Multiple studies conducted worldwide and in the United States demonstrate the potentially significant impact of multidisciplinary tumor board review on the delivery of cancer care and breast cancer in particular.
, [75] [76] [77] [78] [79] [80] [81] Haward et al 81 examined the role of multidisciplinary tumor boards in Great Britain. They demonstrated an increased use of neoadjuvant chemotherapy in patients reviewed at dedicated breast cancer tumor boards; this particular endpoint was utilized as a refl ection of the overall quality of care delivered to patients undergoing comprehensive review.
Similarly, in the United States, the sequential use of axillary staging in therapeutic decision making is primarily described by multidisciplinary treatment groups focusing on breast cancer and involving a variety of specialized providers, including surgeons, medical oncologists, radiation oncologists, radiologists, pathologists, and other practitioners. 23, 75, 82, 83 This approach does not preclude the use of sequential axillary staging and neoadjuvant chemotherapy in settings without formal multidisciplinary review, but it highlights the need for close communication among the entire treatment team throughout the patient's course of care.
Conclusions
Axillary staging for nonmetastatic breast cancer continues to evolve toward less invasive techniques. Routine axillary lymph node dissection (ALND) has been supplanted by sentinel lymph node (SLN) biopsy and now toward axillary ultrasonography as the initial staging examination for women with a breast cancer diagnosis. In recent years, routine axillary ultrasonography for patients with clinically negative axillae and T2 or greater invasive breast cancer has become a growing practice at our institution and others, with minimal or no negative impact on the delivery of care. Not surprisingly, the application of neoadjuvant chemotherapy has grown in parallel with early diagnosis of axillary metastasis.
We do not currently pursue routine axillary ultrasonography in patients with ductal carcinoma in situ or in tumors clinically less than 2 cm. In addition to the diminishing cost-benefi t ratio, overdiagnosis of node-positive disease may subject patients with early-stage clinically node-negative axillae not only to unnecessary testing, but also to unnecessary ALND and the potential long-term sequelae of lymphedema and neuropathy, given the results of the ACOSOG Z0011 study.
In patients with clinically negative axillae on physical and sonographic examinations, the timing of SLN biopsy continues to be a subject of much debate for which no real standard exists. Multiple institutions suggest a step-wise approach to axillary staging and SLN biopsy due to the potential impact of axillary metastasis on both prognostic and therapeutic levels. Even at our institution, the timing of the SLN biopsy is a regular topic of discussion in patients with normal axillary ultrasonograms or negative FNA results who are considered candidates for neoadjuvant chemotherapy. Due to the variation in clinical practice, appropriate preoperative discussion with the patient, the medical oncologist, and other treating clinicians may signifi cantly improve the delivery of care.
As an initial examination for regional nodal tumor spread, the use of axillary ultrasonography is growing in the United States and abroad. Multiple studies have demonstrated safety, effi cacy, and overall cost containment with the addition of axillary ultrasonography as a routine examination for select patients diagnosed with breast cancer. The techniques of axillary ultrasonography and subsequent needle biopsy continue to be refi ned, resulting in improved sensitivity and specifi city for regional disease. Due to the known inaccuracy of physical examination in diagnosing nodal metastasis, we consider sonographically detected axillary metastases as a clinically positive axilla and continue to recommend complete ALND for patients with a positive axillary biopsy, even with a clinically negative axilla, after neoadjuvant chemotherapy. At this point, there is insuffi cient evidence to forgo complete ALND, even with planned breast conservation, in this cohort of patients.
Finally, as treatment decisions become more complex and personalized for breast cancer patients, multidisciplinary review may have a great impact on the overall delivery of cancer care. As the technology of lymphatic mapping and SLN biopsy continues to evolve toward a more selective approach to identify not only the primary draining node but also perhaps the only nodes with metastatic disease, continued discussion regarding the optimal radiologic and surgical approaches for each patient is indicated. At the very least, open lines of communication among clinicians are vital in an increasingly complex decision-making process. We continue to support and provide second opinions for patients and physicians to contribute to cancer care at all levels.
